MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer

Non‑NGS targeted molecular panel tests for predictive cancer testing are covered when all specified criteria are met, including a cancer diagnosis where tumor molecular testing will inform treatment, infeasibility or non‑requirement of NGS, and demonstration that the non‑NGS test identifies the necessary predictive/actionable biomarkers. Coverage also requires MolDX Technical Assessment completion, analytical and clinical validation (including peer‑reviewed evidence), comparable accuracy to NGS with turnaround under 10 business days, and no prior identical panel testing for the same indication.

"Patient has a diagnosis of cancer for which molecular testing of the tumor will inform treatment decisions."

Sign up to see full coverage criteria, indications, and limitations.